Novel Prognostic Index of High-Risk Prostate Cancer Using Simple Summation of Very High-Risk Factors
This study aimed to examine the role of very high-risk (VHR) factors (T3b–4 and Gleason score 9–10) for prognosis of clinically localized high-risk prostate cancer. We reviewed multi-institutional retrospective data of 1413 patients treated with radiotherapy (558 patients treated with external beam...
Gespeichert in:
| Veröffentlicht in: | Cancers 2021-07, Vol.13 (14), p.3486 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 14 |
| container_start_page | 3486 |
| container_title | Cancers |
| container_volume | 13 |
| creator | Yamazaki, Hideya Suzuki, Gen Masui, Koji Aibe, Norihiro Shimizu, Daisuke Kimoto, Takuya Yamada, Kei Shiraishi, Takumi Fujihara, Atsuko Okihara, Koji Yoshida, Ken Nakamura, Satoaki Okabe, Haruumi |
| description | This study aimed to examine the role of very high-risk (VHR) factors (T3b–4 and Gleason score 9–10) for prognosis of clinically localized high-risk prostate cancer. We reviewed multi-institutional retrospective data of 1413 patients treated with radiotherapy (558 patients treated with external beam radiotherapy (EBRT) and 855 patients treated with brachytherapy (BT) ± EBRT. We introduced an index by simple summation of the number of VHR factors—VHR-0, VHR-1, and VHR-2. With median follow-up of 69.6 months, the 5-year biochemical disease free survival rate (bDFS), prostate cancer-specific mortality (PCSM), and distant metastasis-free survival (DMSF) rates were 59.4%, 7.65%, and 83.2% for the VHR-2 group, respectively; 86.7%, 1.50%, and 95.4% for the VHR-1 group, respectively; and 93.1%, 0.12%, and 98.2% for the VHR-0 group, respectively. The VHR-2 group had significantly worse bDFS, PCSM, and DMSF than the VHR-0 (hazard ratios: 4.55, 9.607, and 7.904, respectively) and VHR-1 (hazard ratios: 1.723, 2.391, and 1.491, respectively) groups. The VHR-2 group could be identified as a super high-risk group compared with other groups, and could be a good candidate for clinical trials using multimodal intensified treatments. Simple summation of the number of VHR factors is an easy and useful predictive index for bDFS, PCSM, and DMSF. |
| doi_str_mv | 10.3390/cancers13143486 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8306376</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2555103123</sourcerecordid><originalsourceid>FETCH-LOGICAL-c464t-149589fea09cb4e2a7455e2d998e53e6b2189f815ee1cfbcc013de776ad268153</originalsourceid><addsrcrecordid>eNpdkU1LxDAQhoMoKrpnrwUvXqr5atpcBFlcFRYVv64hm053s7bJmrSi_96siqi5TMj7zDuZGYQOCD5mTOITo52BEAkjnPFKbKBdikuaCyH55q_7DhrFuMTpMEZKUW6jHcaprIQsd1F97V-hzW6Dnzsfe2uyK1fDW-ab7NLOF_mdjc9rNfa6h2z8WTF7jNbNs3vbrVrI7oeu0731bp3zBOH9V-JEm96HuI-2Gt1GGH3HPfQ4OX8YX-bTm4ur8dk0N1zwPidcFpVsQGNpZhyoLnlRAK2lrKBgIGaUJLkiBQAxzcwYTFgNZSl0TUV6Znvo9Mt3Ncw6qA24PuhWrYLtdHhXXlv1V3F2oeb-VVUMC1aKZHD0bRD8ywCxV52NBtpWO_BDVLQoCoIZoSyhh__QpR-CS-2tKc5FmjVP1MkXZdIIY4Dm5zMEq_US1b8lsg-xZo-3</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2554463174</pqid></control><display><type>article</type><title>Novel Prognostic Index of High-Risk Prostate Cancer Using Simple Summation of Very High-Risk Factors</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Yamazaki, Hideya ; Suzuki, Gen ; Masui, Koji ; Aibe, Norihiro ; Shimizu, Daisuke ; Kimoto, Takuya ; Yamada, Kei ; Shiraishi, Takumi ; Fujihara, Atsuko ; Okihara, Koji ; Yoshida, Ken ; Nakamura, Satoaki ; Okabe, Haruumi</creator><creatorcontrib>Yamazaki, Hideya ; Suzuki, Gen ; Masui, Koji ; Aibe, Norihiro ; Shimizu, Daisuke ; Kimoto, Takuya ; Yamada, Kei ; Shiraishi, Takumi ; Fujihara, Atsuko ; Okihara, Koji ; Yoshida, Ken ; Nakamura, Satoaki ; Okabe, Haruumi</creatorcontrib><description>This study aimed to examine the role of very high-risk (VHR) factors (T3b–4 and Gleason score 9–10) for prognosis of clinically localized high-risk prostate cancer. We reviewed multi-institutional retrospective data of 1413 patients treated with radiotherapy (558 patients treated with external beam radiotherapy (EBRT) and 855 patients treated with brachytherapy (BT) ± EBRT. We introduced an index by simple summation of the number of VHR factors—VHR-0, VHR-1, and VHR-2. With median follow-up of 69.6 months, the 5-year biochemical disease free survival rate (bDFS), prostate cancer-specific mortality (PCSM), and distant metastasis-free survival (DMSF) rates were 59.4%, 7.65%, and 83.2% for the VHR-2 group, respectively; 86.7%, 1.50%, and 95.4% for the VHR-1 group, respectively; and 93.1%, 0.12%, and 98.2% for the VHR-0 group, respectively. The VHR-2 group had significantly worse bDFS, PCSM, and DMSF than the VHR-0 (hazard ratios: 4.55, 9.607, and 7.904, respectively) and VHR-1 (hazard ratios: 1.723, 2.391, and 1.491, respectively) groups. The VHR-2 group could be identified as a super high-risk group compared with other groups, and could be a good candidate for clinical trials using multimodal intensified treatments. Simple summation of the number of VHR factors is an easy and useful predictive index for bDFS, PCSM, and DMSF.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers13143486</identifier><identifier>PMID: 34298697</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Biopsy ; Brachytherapy ; Cancer therapies ; Clinical trials ; Hospitals ; Medical prognosis ; Metastases ; Metastasis ; Mortality ; Open data ; Patients ; Prostate cancer ; Radiation therapy ; Risk assessment ; Risk factors ; Risk groups ; Survival</subject><ispartof>Cancers, 2021-07, Vol.13 (14), p.3486</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c464t-149589fea09cb4e2a7455e2d998e53e6b2189f815ee1cfbcc013de776ad268153</citedby><cites>FETCH-LOGICAL-c464t-149589fea09cb4e2a7455e2d998e53e6b2189f815ee1cfbcc013de776ad268153</cites><orcidid>0000-0001-6018-468X ; 0000-0002-6595-0205 ; 0000-0001-7508-7217 ; 0000-0002-8123-3935</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306376/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306376/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Yamazaki, Hideya</creatorcontrib><creatorcontrib>Suzuki, Gen</creatorcontrib><creatorcontrib>Masui, Koji</creatorcontrib><creatorcontrib>Aibe, Norihiro</creatorcontrib><creatorcontrib>Shimizu, Daisuke</creatorcontrib><creatorcontrib>Kimoto, Takuya</creatorcontrib><creatorcontrib>Yamada, Kei</creatorcontrib><creatorcontrib>Shiraishi, Takumi</creatorcontrib><creatorcontrib>Fujihara, Atsuko</creatorcontrib><creatorcontrib>Okihara, Koji</creatorcontrib><creatorcontrib>Yoshida, Ken</creatorcontrib><creatorcontrib>Nakamura, Satoaki</creatorcontrib><creatorcontrib>Okabe, Haruumi</creatorcontrib><title>Novel Prognostic Index of High-Risk Prostate Cancer Using Simple Summation of Very High-Risk Factors</title><title>Cancers</title><description>This study aimed to examine the role of very high-risk (VHR) factors (T3b–4 and Gleason score 9–10) for prognosis of clinically localized high-risk prostate cancer. We reviewed multi-institutional retrospective data of 1413 patients treated with radiotherapy (558 patients treated with external beam radiotherapy (EBRT) and 855 patients treated with brachytherapy (BT) ± EBRT. We introduced an index by simple summation of the number of VHR factors—VHR-0, VHR-1, and VHR-2. With median follow-up of 69.6 months, the 5-year biochemical disease free survival rate (bDFS), prostate cancer-specific mortality (PCSM), and distant metastasis-free survival (DMSF) rates were 59.4%, 7.65%, and 83.2% for the VHR-2 group, respectively; 86.7%, 1.50%, and 95.4% for the VHR-1 group, respectively; and 93.1%, 0.12%, and 98.2% for the VHR-0 group, respectively. The VHR-2 group had significantly worse bDFS, PCSM, and DMSF than the VHR-0 (hazard ratios: 4.55, 9.607, and 7.904, respectively) and VHR-1 (hazard ratios: 1.723, 2.391, and 1.491, respectively) groups. The VHR-2 group could be identified as a super high-risk group compared with other groups, and could be a good candidate for clinical trials using multimodal intensified treatments. Simple summation of the number of VHR factors is an easy and useful predictive index for bDFS, PCSM, and DMSF.</description><subject>Biopsy</subject><subject>Brachytherapy</subject><subject>Cancer therapies</subject><subject>Clinical trials</subject><subject>Hospitals</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Mortality</subject><subject>Open data</subject><subject>Patients</subject><subject>Prostate cancer</subject><subject>Radiation therapy</subject><subject>Risk assessment</subject><subject>Risk factors</subject><subject>Risk groups</subject><subject>Survival</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkU1LxDAQhoMoKrpnrwUvXqr5atpcBFlcFRYVv64hm053s7bJmrSi_96siqi5TMj7zDuZGYQOCD5mTOITo52BEAkjnPFKbKBdikuaCyH55q_7DhrFuMTpMEZKUW6jHcaprIQsd1F97V-hzW6Dnzsfe2uyK1fDW-ab7NLOF_mdjc9rNfa6h2z8WTF7jNbNs3vbrVrI7oeu0731bp3zBOH9V-JEm96HuI-2Gt1GGH3HPfQ4OX8YX-bTm4ur8dk0N1zwPidcFpVsQGNpZhyoLnlRAK2lrKBgIGaUJLkiBQAxzcwYTFgNZSl0TUV6Znvo9Mt3Ncw6qA24PuhWrYLtdHhXXlv1V3F2oeb-VVUMC1aKZHD0bRD8ywCxV52NBtpWO_BDVLQoCoIZoSyhh__QpR-CS-2tKc5FmjVP1MkXZdIIY4Dm5zMEq_US1b8lsg-xZo-3</recordid><startdate>20210712</startdate><enddate>20210712</enddate><creator>Yamazaki, Hideya</creator><creator>Suzuki, Gen</creator><creator>Masui, Koji</creator><creator>Aibe, Norihiro</creator><creator>Shimizu, Daisuke</creator><creator>Kimoto, Takuya</creator><creator>Yamada, Kei</creator><creator>Shiraishi, Takumi</creator><creator>Fujihara, Atsuko</creator><creator>Okihara, Koji</creator><creator>Yoshida, Ken</creator><creator>Nakamura, Satoaki</creator><creator>Okabe, Haruumi</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6018-468X</orcidid><orcidid>https://orcid.org/0000-0002-6595-0205</orcidid><orcidid>https://orcid.org/0000-0001-7508-7217</orcidid><orcidid>https://orcid.org/0000-0002-8123-3935</orcidid></search><sort><creationdate>20210712</creationdate><title>Novel Prognostic Index of High-Risk Prostate Cancer Using Simple Summation of Very High-Risk Factors</title><author>Yamazaki, Hideya ; Suzuki, Gen ; Masui, Koji ; Aibe, Norihiro ; Shimizu, Daisuke ; Kimoto, Takuya ; Yamada, Kei ; Shiraishi, Takumi ; Fujihara, Atsuko ; Okihara, Koji ; Yoshida, Ken ; Nakamura, Satoaki ; Okabe, Haruumi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c464t-149589fea09cb4e2a7455e2d998e53e6b2189f815ee1cfbcc013de776ad268153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biopsy</topic><topic>Brachytherapy</topic><topic>Cancer therapies</topic><topic>Clinical trials</topic><topic>Hospitals</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Mortality</topic><topic>Open data</topic><topic>Patients</topic><topic>Prostate cancer</topic><topic>Radiation therapy</topic><topic>Risk assessment</topic><topic>Risk factors</topic><topic>Risk groups</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamazaki, Hideya</creatorcontrib><creatorcontrib>Suzuki, Gen</creatorcontrib><creatorcontrib>Masui, Koji</creatorcontrib><creatorcontrib>Aibe, Norihiro</creatorcontrib><creatorcontrib>Shimizu, Daisuke</creatorcontrib><creatorcontrib>Kimoto, Takuya</creatorcontrib><creatorcontrib>Yamada, Kei</creatorcontrib><creatorcontrib>Shiraishi, Takumi</creatorcontrib><creatorcontrib>Fujihara, Atsuko</creatorcontrib><creatorcontrib>Okihara, Koji</creatorcontrib><creatorcontrib>Yoshida, Ken</creatorcontrib><creatorcontrib>Nakamura, Satoaki</creatorcontrib><creatorcontrib>Okabe, Haruumi</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamazaki, Hideya</au><au>Suzuki, Gen</au><au>Masui, Koji</au><au>Aibe, Norihiro</au><au>Shimizu, Daisuke</au><au>Kimoto, Takuya</au><au>Yamada, Kei</au><au>Shiraishi, Takumi</au><au>Fujihara, Atsuko</au><au>Okihara, Koji</au><au>Yoshida, Ken</au><au>Nakamura, Satoaki</au><au>Okabe, Haruumi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel Prognostic Index of High-Risk Prostate Cancer Using Simple Summation of Very High-Risk Factors</atitle><jtitle>Cancers</jtitle><date>2021-07-12</date><risdate>2021</risdate><volume>13</volume><issue>14</issue><spage>3486</spage><pages>3486-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>This study aimed to examine the role of very high-risk (VHR) factors (T3b–4 and Gleason score 9–10) for prognosis of clinically localized high-risk prostate cancer. We reviewed multi-institutional retrospective data of 1413 patients treated with radiotherapy (558 patients treated with external beam radiotherapy (EBRT) and 855 patients treated with brachytherapy (BT) ± EBRT. We introduced an index by simple summation of the number of VHR factors—VHR-0, VHR-1, and VHR-2. With median follow-up of 69.6 months, the 5-year biochemical disease free survival rate (bDFS), prostate cancer-specific mortality (PCSM), and distant metastasis-free survival (DMSF) rates were 59.4%, 7.65%, and 83.2% for the VHR-2 group, respectively; 86.7%, 1.50%, and 95.4% for the VHR-1 group, respectively; and 93.1%, 0.12%, and 98.2% for the VHR-0 group, respectively. The VHR-2 group had significantly worse bDFS, PCSM, and DMSF than the VHR-0 (hazard ratios: 4.55, 9.607, and 7.904, respectively) and VHR-1 (hazard ratios: 1.723, 2.391, and 1.491, respectively) groups. The VHR-2 group could be identified as a super high-risk group compared with other groups, and could be a good candidate for clinical trials using multimodal intensified treatments. Simple summation of the number of VHR factors is an easy and useful predictive index for bDFS, PCSM, and DMSF.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>34298697</pmid><doi>10.3390/cancers13143486</doi><orcidid>https://orcid.org/0000-0001-6018-468X</orcidid><orcidid>https://orcid.org/0000-0002-6595-0205</orcidid><orcidid>https://orcid.org/0000-0001-7508-7217</orcidid><orcidid>https://orcid.org/0000-0002-8123-3935</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2021-07, Vol.13 (14), p.3486 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8306376 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Biopsy Brachytherapy Cancer therapies Clinical trials Hospitals Medical prognosis Metastases Metastasis Mortality Open data Patients Prostate cancer Radiation therapy Risk assessment Risk factors Risk groups Survival |
| title | Novel Prognostic Index of High-Risk Prostate Cancer Using Simple Summation of Very High-Risk Factors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T23%3A48%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20Prognostic%20Index%20of%20High-Risk%20Prostate%20Cancer%20Using%20Simple%20Summation%20of%20Very%20High-Risk%20Factors&rft.jtitle=Cancers&rft.au=Yamazaki,%20Hideya&rft.date=2021-07-12&rft.volume=13&rft.issue=14&rft.spage=3486&rft.pages=3486-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers13143486&rft_dat=%3Cproquest_pubme%3E2555103123%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2554463174&rft_id=info:pmid/34298697&rfr_iscdi=true |